TARS (Tarsus Pharmaceuticals) Total Tax Payable: $0.6 Mil (As of Mar. 2026)


TARS Tarsus Pharmaceuticals Inc TARS
47 GF Score
Price $67.72
GF Value $204.46
Valuation Possible Value Trap
! 2 Warning Signs
View Full Analysis

What is Tarsus Pharmaceuticals Total Tax Payable?

Tarsus Pharmaceuticals TARS -4.02% 47 Total Tax Payable is $0.6 Mil as of Mar. 2026. GuruFocus rates TARS with a GF Score™ of 47/100 and a GF Value™ of $204.46 (Possible Value Trap). The stock has 2 warning signs investors should review.

Tarsus Pharmaceuticals's Total Tax Payable for the quarter that ended in Mar. 2026 was $0.6 Mil.

Tarsus Pharmaceuticals's quarterly Total Tax Payable increased from Sep. 2025 ($0.0 Mil) to Dec. 2025 ($1.8 Mil) but then declined from Dec. 2025 ($1.8 Mil) to Mar. 2026 ($0.6 Mil).

Tarsus Pharmaceuticals's annual Total Tax Payable stayed the same from Dec. 2023 ($0.0 Mil) to Dec. 2024 ($0.0 Mil) but then increased from Dec. 2024 ($0.0 Mil) to Dec. 2025 ($1.8 Mil).

Tarsus Pharmaceuticals Total Tax Payable Related Terms

Tarsus Pharmaceuticals Total Tax Payable Historical Data

* Premium members only.

The historical data trend for Tarsus Pharmaceuticals's Total Tax Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tarsus Pharmaceuticals Total Tax Payable Chart

Tarsus Pharmaceuticals Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Tax Payable
Get a 7-Day Free Trial 0.06 0.00 0.00 0.00 1.81

Tarsus Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Tax Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 1.81 0.56
TARS
47GF Score
Tarsus Pharmaceuticals Inc TARS
Total Tax Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Tarsus Pharmaceuticals Total Tax Payable Calculation

Total Tax Payable is the taxes liability owed to federal, state, and local tax authorities. It is the carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes.

Frequently Asked Questions Learn more about Total Tax Payable →
What does a Total Tax Payable of $0.6 Mil mean?
Tarsus Pharmaceuticals (TARS) has a Total Tax Payable of $0.6 Mil as of Mar. 2026. Tax Payable is the taxes liability owed to federal, state, and local tax authorities. View historical data on Tarsus Pharmaceuticals and its competitors.
Is Tarsus Pharmaceuticals' Total Tax Payable too high?
Tarsus Pharmaceuticals' current Total Tax Payable is $0.6 Mil. Overall, Tarsus Pharmaceuticals has a GF Score™ of 47/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Tarsus Pharmaceuticals' Total Tax Payable compare to KLRA and CLDX?
Tarsus Pharmaceuticals' Total Tax Payable of $0.6 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Tax Payable for a Biotechnology company?
A good Total Tax Payable depends on the Biotechnology industry context. However, Total Tax Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Tax Payable mean?
A high Total Tax Payable can signal that a stock is expensive relative to its fundamentals. Tax Payable is the taxes liability owed to federal, state, and local tax authorities. View historical data on Tarsus Pharmaceuticals and its competitors. Tarsus Pharmaceuticals's current Total Tax Payable is $0.6 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tarsus Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Tarsus Pharmaceuticals (TARS) is currently considered Possible Value Trap. The stock's GF Value™ is $204.46, compared to a current price of $67.72 — trading 66.9% below its estimated fair value. The current Total Tax Payable is $0.6 Mil. Tarsus Pharmaceuticals' overall GF Score™ is 47/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Tax Payable calculated?
Total Tax Payable is calculated from a company's financial statements. For Tarsus Pharmaceuticals (TARS), the current Total Tax Payable is $0.6 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Tarsus Pharmaceuticals (TARS) Overvalued in 2026?

Based on GuruFocus' analysis, Tarsus Pharmaceuticals stock appears to be undervalued. The current stock price of $67.72 is trading 66.9% below its estimated GF Value™ of $204.46. GuruFocus considers Tarsus Pharmaceuticals to be Possible Value Trap.

Key valuation signals for TARS:

  • Total Tax Payable: $0.6 Mil
  • GF Value™: $204.46 vs. price of $67.72 (66.9% below fair value)
  • GF Score™: 47/100 with 2 warning signs

No single metric tells the full story. See the TARS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Tarsus Pharmaceuticals Business Description

Address 15440 Laguna Canyon Road, Suite 160, Irvine, CA, USA, 92618
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.
47GF Score

Get the complete analysis for TARS

Total Tax Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$67.72
Price
$204.46
GF Value